WO2000030640A1 - Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia - Google Patents
Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia Download PDFInfo
- Publication number
- WO2000030640A1 WO2000030640A1 PCT/EP1999/009048 EP9909048W WO0030640A1 WO 2000030640 A1 WO2000030640 A1 WO 2000030640A1 EP 9909048 W EP9909048 W EP 9909048W WO 0030640 A1 WO0030640 A1 WO 0030640A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prucalopride
- dyspeptic symptoms
- use according
- addition salt
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Definitions
- the present invention is concerned with the use of prucalopride and pharmaceutically acceptable acid addition salts thereof for the manufacture of a medicament for the treatment of warm-blooded animals, including humans, suffering from dyspeptic symptoms.
- Prucalopride which is the generic name for the (1 : 1) succinic acid addition salt of 4-amino-5-chloro-2,3-dihydro-N-[ 1 -(3-methoxypropyl)-4-piperidinyl]-7-benzofuran- carboxamide, has enterokinetic properties, i.e. it has strong gastrointestinal prokinetic activities.
- Prucalopride facilitates both cholinergic and non-cholinergic non-adrenergic (NANC) excitatory neurotransmission and stimulates colonic motility and defecation in animals. It has no affinity for 5-HT2 A and 5-HT 3A receptors but is a potent and selective agonist of 5-HT 4 receptors. Prucalopride induces giant contractions in the colon that are propagated over the length of the colon as a peristaltic wave and therefore has significant motility enhancing effects on the large intestine.
- NANC non-cholinergic non-adrenergic
- Prucalopride is generically described in EP-0,445,862-Al , published on 1 1 September
- prucalopride as used herein comprises the free base form and the pharmaceutically acceptable acid addition salts thereof.
- Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, /?-aminosalicylic, pamoic and the like acids.
- inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids
- organic acids
- addition salt as used hereinabove also comprises the solvates which prucalopride as well as the salts thereof, are able to form.
- Such solvates are for example hydrates, alcoholates and the like.
- Preferred pharmaceutically acceptable acid addition salts of 4-amino-5-chloro-2,3- dihydro-N-[ 1 -(3-methoxypropyl)-4-piperidinyl]-7-benzofuran-carboxamide are the hydrochloric acid (1 : 1) addition salt and the succinic acid (1: 1) addition salt.
- prucalopride is useful in the treatment of motility disorders of the intestinal system, such as, e.g. constipation, pseudo-obstruction, intestinal atony, post-operative intestinal atony, irritable bowel syndrome (IBS), and drug-induced delayed transit.
- motility disorders of the intestinal system such as, e.g. constipation, pseudo-obstruction, intestinal atony, post-operative intestinal atony, irritable bowel syndrome (IBS), and drug-induced delayed transit.
- prucalopride is also useful to treat patients suffering from dyspeptic symptoms.
- Dyspepsia is a very common disorder. In fact, between 15 to 20 percent of the population suffers from it on a recurring basis.
- Dyspepsia can originate from a number of causes. For instance dyspeptic symptoms can be caused by a disturbed accommodation of food, hypersensitivity either peripherally or centrally mediated, disturbed gastric emptying, disturbed electrical rhythm, disturbed antro-duodenal coordination, or an impaired response to the intraluminal contents.
- Dyspeptic symptoms are for example a lack of appetite, feeling of fullness, early satiety, nausea, vomiting, bloating and gaseous eructation.
- the present invention also provides a method of treating warm-blooded animals, including humans, (generally called herein patients) suffering from dyspeptic symptoms such as, e.g. a lack of appetite, feeling of fullness, early satiety, nausea, vomiting, bloating and gaseous eructation. Consequently a method of treatment is provided for relieving patients suffering from dyspeptic symptoms, in particular dyspeptic symptoms caused by a decreased motility of the colon, by administering to said patients a therapeutically effective amount of prucalopride or a pharmaceutically acceptable acid addition salt thereof.
- dyspeptic symptoms such as, e.g. a lack of appetite, feeling of fullness, early satiety, nausea, vomiting, bloating and gaseous eructation. Consequently a method of treatment is provided for relieving patients suffering from dyspeptic symptoms, in particular dyspeptic symptoms caused by a decreased motility of the colon, by administering to said patients a therapeutically effective amount of prucalopride or a pharmaceutically acceptable acid addition salt
- the present invention provides the use of prucalopride for the manufacture of a medicament for treating dyspeptic symptoms, in particular dyspeptic symptoms caused by a decreased motility of the colon. Both prophylactic and therapeutic treatment are envisaged.
- compositions of this invention an effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
- a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
- These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally or by parenteral injection.
- any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
- the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
- injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
- Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
- Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
- a therapeutically effective amount would be from about 0.001 mg/kg to about 5 mg/kg body weight, preferably from about 0.01 mg/kg to about 0.5 mg/kg body weight.
- a method of treatment may also include administering the active ingredient on a regimen of between two or four intakes per day.
- prucalopride. or a pharmaceutically acceptable acid addition salt thereof, required as daily dose in treatment will vary not only with the route of administration, the nature of the condition being treated and the age, weight and condition of the patient and will ultimately be at the discretion of the attendant physician. In general, however, a suitable daily dose will be in the range of from about 0.05 to about 200 mg per day, in particular from about 0.1 to 20 mg per day. more particular from about 0.5 to 10 mg per day. A suitable daily dose for use in prophylaxis will generally be in the same range. It may be appropriate to administer the required dose as two, three, four or more sub- doses at appropriate intervals throughout the day. Administration can be before or after the intake of food (i.e. preprandial or postprandial).
- prucalopride or a pharmaceutically acceptable acid addition salt thereof, to treat subjects suffering from dyspeptic symptoms
- the efficacy of prucalopride, or a pharmaceutically acceptable acid addition salt thereof, to treat subjects suffering from dyspeptic symptoms can be demonstrated by the following trial.
- a group of healthy subjects is treated with an anti-diarrheal compound such as, e.g. loperamide, which causes a mild constipation in said subjects, i.e. the normal colon motility is reduced so that the subjects have a colon in a "filled" condition.
- an anti-diarrheal compound such as, e.g. loperamide
- the group of subjects is split into a control group and a test group for treatment with prucalopride.
- the subjects in the test group are then treated with prucalopride.
- the subjects in both groups are served a standard breakfast consisting of four slices of bread, one slice of ham, one slice of cheese, butter, jelly and two cups of coffee or tea with, if desired, milk and/or sugar.
- the number of subjects suffering from dyspeptic symptoms and the seriousness of the dyspeptic symptoms are recorded and compared between the test group and the control group.
- the above described trial can be modified by treating the test group with prucalopride after the subjects have finished their meal.
- the trial can be done open, or blindfolded, using a randomized group of subjects.
- a sub-group of subjects can be selected also having reduced colon motility.
- Said sub-group can be given prucalopride, or a pharmaceutically acceptable acid addition salt thereof, either preprandial or postprandial and the reduction of the number or seriousness of the dyspeptic symptoms can be recorded.
- a sub-group of subjects can be selected also having dyspeptic symptoms.
- Said sub-group can be given prucalopride, or a pharmaceutically acceptable acid addition salt thereof, either preprandial or postprandial and the reduction of the number or seriousness of the dyspeptic symptoms can be recorded.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002352278A CA2352278A1 (en) | 1998-11-23 | 1999-11-16 | Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia |
JP2000583523A JP2002530334A (en) | 1998-11-23 | 1999-11-16 | Use of prucalopride for the manufacture of a medicament for the treatment of indigestion |
EP99972536A EP1135130A1 (en) | 1998-11-23 | 1999-11-16 | Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia |
NZ511117A NZ511117A (en) | 1998-11-23 | 1999-11-16 | Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia |
KR1020017004376A KR20010080025A (en) | 1998-11-23 | 1999-11-16 | Use of Prucalopride for the Manufacture of a Medicament for the Treatment of Dyspepsia |
AU13857/00A AU770580B2 (en) | 1998-11-23 | 1999-11-16 | Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98203943 | 1998-11-23 | ||
EP98203943.0 | 1998-11-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000030640A1 true WO2000030640A1 (en) | 2000-06-02 |
Family
ID=8234369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/009048 WO2000030640A1 (en) | 1998-11-23 | 1999-11-16 | Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1135130A1 (en) |
JP (1) | JP2002530334A (en) |
KR (1) | KR20010080025A (en) |
AU (1) | AU770580B2 (en) |
CA (1) | CA2352278A1 (en) |
NZ (1) | NZ511117A (en) |
WO (1) | WO2000030640A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000066170A1 (en) * | 1999-04-29 | 2000-11-09 | Janssen Pharmaceutica N.V. | Prucalopride oral solution |
WO2003059906A1 (en) * | 2002-01-16 | 2003-07-24 | Janssen Pharmaceutica N.V. | Prucalopride-n-oxide |
EP1493441A1 (en) * | 2002-04-08 | 2005-01-05 | Zeria Pharmaceutical Co., Ltd. | Therapeutic agent for food competence disorder in stomach |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0389037A1 (en) * | 1989-03-22 | 1990-09-26 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives |
EP0445862A2 (en) * | 1990-03-06 | 1991-09-11 | Janssen Pharmaceutica N.V. | N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2H-benzopyran)carboxamide derivatives |
WO1996016060A1 (en) * | 1994-11-24 | 1996-05-30 | Janssen Pharmaceutica N.V. | Enterokinetic benzamide |
-
1999
- 1999-11-16 CA CA002352278A patent/CA2352278A1/en not_active Abandoned
- 1999-11-16 KR KR1020017004376A patent/KR20010080025A/en not_active Application Discontinuation
- 1999-11-16 EP EP99972536A patent/EP1135130A1/en not_active Withdrawn
- 1999-11-16 JP JP2000583523A patent/JP2002530334A/en not_active Withdrawn
- 1999-11-16 WO PCT/EP1999/009048 patent/WO2000030640A1/en not_active Application Discontinuation
- 1999-11-16 AU AU13857/00A patent/AU770580B2/en not_active Ceased
- 1999-11-16 NZ NZ511117A patent/NZ511117A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0389037A1 (en) * | 1989-03-22 | 1990-09-26 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives |
EP0445862A2 (en) * | 1990-03-06 | 1991-09-11 | Janssen Pharmaceutica N.V. | N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2H-benzopyran)carboxamide derivatives |
WO1996016060A1 (en) * | 1994-11-24 | 1996-05-30 | Janssen Pharmaceutica N.V. | Enterokinetic benzamide |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000066170A1 (en) * | 1999-04-29 | 2000-11-09 | Janssen Pharmaceutica N.V. | Prucalopride oral solution |
US6413988B1 (en) | 1999-04-29 | 2002-07-02 | Janssen Pharmaceutica N.V. | Prucalopride oral solution |
JP2002543161A (en) * | 1999-04-29 | 2002-12-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Prucalopride oral solution |
MY119880A (en) * | 1999-04-29 | 2005-07-29 | Janssen Pharmaceutica Nv | Prucalopride oral solution |
HRP20010764B1 (en) * | 1999-04-29 | 2011-01-31 | Janssen Pharmaceutica N.V. | Prucalopride oral solution |
JP4773619B2 (en) * | 1999-04-29 | 2011-09-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Purcarapride oral solution |
WO2003059906A1 (en) * | 2002-01-16 | 2003-07-24 | Janssen Pharmaceutica N.V. | Prucalopride-n-oxide |
US8063069B2 (en) | 2002-01-16 | 2011-11-22 | Janssen Pharmaceutica N.V. | Prucalopride-N-oxide |
EP1493441A1 (en) * | 2002-04-08 | 2005-01-05 | Zeria Pharmaceutical Co., Ltd. | Therapeutic agent for food competence disorder in stomach |
EP1493441A4 (en) * | 2002-04-08 | 2007-10-17 | Zeria Pharm Co Ltd | Therapeutic agent for food competence disorder in stomach |
Also Published As
Publication number | Publication date |
---|---|
AU1385700A (en) | 2000-06-13 |
JP2002530334A (en) | 2002-09-17 |
AU770580B2 (en) | 2004-02-26 |
CA2352278A1 (en) | 2000-06-02 |
NZ511117A (en) | 2002-11-26 |
KR20010080025A (en) | 2001-08-22 |
EP1135130A1 (en) | 2001-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2159614C2 (en) | Cryogenically dried ondasteron compositions and method for treating mammals | |
Leung et al. | Weight management and current options in pharmacotherapy: orlistat and sibutramine | |
KR100204115B1 (en) | Immediate release ph-independent solid dosage form of cisapride | |
Ballinger | Orlistat in the treatment of obesity | |
JP3977724B2 (en) | Pharmaceutical composition | |
IL110510A (en) | Pharmaceutical preparation containing a glucosidase and/or amylase inhibitor and a lipase inhibitor | |
JP2005528431A (en) | NMDA-antagonist and acetylcholinesterase inhibitor combination for treating Alzheimer's disease | |
US20130310454A1 (en) | Pharmaceutical composition comprising extract of lonicera japonica for prevention and treatment of gastroesophageal reflux disease | |
JP2000516198A (en) | Use of a 5HT4 receptor antagonist to overcome the gastrointestinal effects of serotonin reuptake inhibitors | |
EP1825857A1 (en) | Agent for ameliorating the maximum passage time through digestive tract, agent for ameliorating passage time through digestive tract and preventive for colon cancer | |
CA2704728A1 (en) | Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors | |
EP0707492A1 (en) | H 2? antagonist-gastrointestinal motility agent combinations | |
JP2007051134A (en) | Utilization of d-allose and d-psicose for anti-neurogenic pain effect | |
CA2311423C (en) | Method for treating hyperlipidemia | |
AU770580B2 (en) | Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia | |
WO2019126579A1 (en) | Colchicine formulations and methods of use | |
CN103813792B (en) | Be used for the treatment of the YM-905 of overactive bladder and the combination of saliva stimulant | |
Ali et al. | Role of prucalopride in treating functional constipation and gastroparesis: a systemic review | |
JP3465247B2 (en) | Prevention and treatment of arteriosclerosis | |
JP2022532643A (en) | Strains showing liver function improving activity and their uses | |
JP2004194635A (en) | Diet food | |
JP2002226369A (en) | Glutamine-containing oral composition | |
KR20070112546A (en) | Food composition comprising extracts from lycium chinenses mill | |
JPWO2011034006A1 (en) | Composition for lowering uric acid level in blood | |
KR20090027383A (en) | Composition for preventing or treating hyperlipidemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 13857 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999972536 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017004376 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 511117 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 583523 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09856436 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2352278 Country of ref document: CA Ref country code: CA Ref document number: 2352278 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13857/00 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017004376 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1999972536 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999972536 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 13857/00 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017004376 Country of ref document: KR |